Chiome Bioscience Inc. (4583.T) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 5Aug 10Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−4.7x

Market Cap

JPY 5.58B

MomentumView details →

1D Return

+1.23%

YTD Return

+4.67%

RSI (14)

86.0

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−4.7x

Market Cap

JPY 5.58B

RSI (14)

86.0

MomentumView details →

1D Return

+1.23%

YTD Return

+4.67%

ProfitabilityView details →

Gross Margin

59.96%

Net Margin

−165.60%

EBITDA Margin

−164.46%

ROE (TTM)

−87.52%

ROA (TTM)

−56.86%

Asset Turnover

0.36x

GrowthView details →

Revenue YoY

−23.97%

EPS YoY

+20.99%

FCF YoY

—

Revenue CAGR 3Y

−2.00%

EPS CAGR 3Y

+17.50%

EBITDA YoY

—

EarningsView details →

EPS (Actual)

—

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

—

Avg Surprise (4Q)

—

Rev Surprise

—

Capital & dividendView details →

Debt/Equity

0.23x

Current Ratio

4.13x

Quick Ratio

3.99x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

Financials snapshotView financials →

Revenue (TTM)

602.00M

Net Income (TTM)

−949.00M

Op. CF (TTM)

—

Next earningsNov 17, 2026 →

Latest newsMore news →

Caom Bioscience signed a joint research agreement with Fronteo to create bispecific antibody drugs using AI technology.2d ago

Similar companies

NIPPON CHEMIPHAR CO.,LTD.4539.T BrightPath Biotherapeutics Co.,Ltd.4594.T Cyfuse Biomedical K.K.4892.T Chordia Therapeutics Inc.190A.T J-Pharma Co.,Ltd.520A.T Noile-Immune Biotech Inc.4893.T Find similar companies →

Latest newsMore news →

Caom Bioscience signed a joint research agreement with Fronteo to create bispecific antibody drugs using AI technology.2d ago